Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell…

This article was originally published here

Onco Targets Ther. 2021 Apr 6;14:2349-2361. doi: 10.2147/OTT.S300834. eCollection 2021.

ABSTRACT

PURPOSE: Recently, the British Myeloma Research Alliance put forward a Myeloma Risk Profile (MRP) for the first time to stratify the prognosis risk of non-transplanted patients with multiple myeloma. However, only limited studies have evaluated the applicability of this model in the Chinese population. This study aimed to estimate the prognostic value of MRP in newly diagnosed multiple myeloma patients without autologous stem cell transplantation in China.

PATIENTS AND METHODS: Patients with multiple myeloma in Wuxi Peoples Hospital from January 1, 2007, to June 30, 2018 were evaluated based on the MRP score, and the relationship between the clinical outcome of patients with MM and the score was analyzed retrospectively.

RESULTS: First, significant differences were observed in the overall survival (OS) (P<0.05) and progression-free survival (PFS) (P<0.05) between the low-, middle-, and high-risk groups. Second, in the bortezomib treatment subgroup and complex chromosome karyotype subgroup, OS and PFS were significantly shorter in the high-risk group than in the low-risk group (P<0.05). Third, the depth of remission still showed prognostic significance in the high-risk MRP group.

CONCLUSION: MRP is also applicable in Chinese patients with newly diagnosed MM who did not undergo transplantation, as it is simple and cost effective; hence, it is worth popularizing.

PMID:33854333 | PMC:PMC8039846 | DOI:10.2147/OTT.S300834

See the original post:

Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell...